- The trend backdrop is active with a 12-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
MANKIND
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Mankind Pharma Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
2,456 INR
-0.6%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 8.0% above the Trend Line and sits at 71.5% of its 52-week range. The latest completed week returned -0.6%, after a -2.7% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 47/100. Near-term considerations: volume confirmation is below normal.
Setup score
55
out of 100
Latest Close
2,456 INR
7 Aug 2026
1W Return
-0.6%
latest completed week
4W Return
-2.7%
short-term follow-through
12W Return
-1.9%
quarterly tape
Trend Breadth
40.4%
21 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- No major top-level risk cluster is currently dominant.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.6%
Latest completed week; four-week move -2.7%.
Indicator stack
64/60
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
47/100
24 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 8.0% above the Trend Line and sits at 71.5% of its 52-week range. The latest completed week returned -0.6%, after a -2.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7412-week average 0.58
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.74Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -2.7% over four weeks, -1.9% over 12 weeks, and -0.4% over one year. The current trend has remained active for 12 consecutive weeks.
Performance by holding period
Active trend streak12 weeks
Active weeks in one year21
Trend breadth40.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.70Latest activity-pressure read.
Pressure change-28.5%Four-week change in activity pressure.
Leadership6.66Latest relative-leadership reading.
RS change-40.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength42/100Blend of value, momentum, and quality. Underlying universe rank 59; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality92/100Profitability and accounting quality. Underlying universe rank 9; rank 1 is best.
Momentum65/100Medium-term price momentum. Underlying universe rank 36; rank 1 is best.
Growth38/100Revenue and earnings growth. Underlying universe rank 63; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework36/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 55.7x Price divided by trailing earnings.
- Price / sales
- 7.4x Market value relative to trailing revenue.
- EV / EBITDA
- 28.5x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 2.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 71.7% Gross profit retained from each unit of revenue.
- Operating margin
- 18.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 17.5% Free cash flow generated from revenue.
- Return on invested capital
- 8.4% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 17.0% Latest one-year revenue growth.
- EPS growth
- -4.0% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 26.6% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- -0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment47/100
Weighted news tone is neutral across 24 relevant articles.
7 positive · 15 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-8.2%Distance below the 52-week high.
13-week volatility2.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+11.0%Week of 27 Feb.
Worst week-6.5%Week of 20 Mar.
Latest week-0.6%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains9
Flat weeks0
Modest losses11
Sharp losses2
Recent vol2.0%13-week weekly-return volatility.
Base vol3.3%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew2.5% / -2.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank70 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank57 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape58/100
Trend, activity pressure, participation, and risk combine to a 58/100 tape read.
Indicator analysis87/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.74; No reversal markers Factors53/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 72 SVQF36/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1006.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment47/100Weighted news tone is neutral across 24 relevant articles.
Mankind Pharma to attend three Mumbai investor conferences in August Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 2,456 INR | -0.6% | 2,274 INR | 2,290 INR | 0.70 | 6.66 | 1.6M | On |
| 31 Jul 2026 | 2,470 INR | -1.5% | 2,266 INR | 2,286 INR | 0.95 | 8.05 | 3.8M | On |
| 24 Jul 2026 | 2,507 INR | 0.9% | 2,257 INR | 2,282 INR | 1.05 | 12.47 | 1.5M | On |
| 17 Jul 2026 | 2,484 INR | -1.6% | 2,247 INR | 2,278 INR | 1.05 | 8.85 | 2.5M | On |
| 10 Jul 2026 | 2,525 INR | -0.1% | 2,236 INR | 2,274 INR | 0.98 | 11.13 | 1.5M | On |
| 3 Jul 2026 | 2,529 INR | 2.7% | 2,225 INR | 2,270 INR | 0.86 | 11.04 | 392.4K | On |
| 26 Jun 2026 | 2,462 INR | 2.0% | 2,214 INR | 2,265 INR | 0.72 | 9.28 | 0 | On |
| 19 Jun 2026 | 2,414 INR | 1.4% | 2,207 INR | 2,260 INR | 0.78 | 7.59 | 484.8K | On |
| 12 Jun 2026 | 2,381 INR | 1.9% | 2,201 INR | 2,255 INR | 0.92 | 8.08 | 286.1K | On |
| 5 Jun 2026 | 2,336 INR | -1.7% | 2,197 INR | 2,250 INR | 1.10 | 7.29 | 160.2K | On |
| 29 May 2026 | 2,376 INR | -4.2% | 2,195 INR | 2,245 INR | 1.33 | 8.40 | 3.9M | On |
| 22 May 2026 | 2,479 INR | -0.9% | 2,195 INR | 2,239 INR | 1.25 | 12.35 | 7.5M | On |
| 15 May 2026 | 2,503 INR | 3.0% | 2,194 INR | 2,232 INR | 1.22 | 13.94 | 3.4M | Off |
| 8 May 2026 | 2,431 INR | 8.2% | 2,193 INR | 2,224 INR | 0.99 | 8.28 | 3.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.